|
Developed under the direction and sponsorship of Sanofi US and Regeneron Pharmaceuticals, Inc.
|
|
|
|
INDICATION
|
|
DUPIXENT® (dupilumab) is indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.
|
|
IMPORTANT SAFETY INFORMATION
|
|
CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.
|
|
Please see additional Important Safety Information below.
|
|
|
|
|
Paid consultant
|
|
|
|
My name is Lauren Miller, a dermatology PA. Because of the proven efficacy data and demonstrated safety profile, I consider DUPIXENT® (dupilumab) for my patients aged 6+ months with uncontrolled moderate-to-severe atopic dermatitis. Find more resources below for information about pediatric clinical trial data.
Lauren E. Miller, MPAS, PA-C
|
|
|
|
|
|
|
  
|
|
|
In patients aged 6 months to 5 years with uncontrolled moderate-to-severe atopic dermatitis
|
Demonstrated
Results in Itch and Skin Lesions
|
Real patient being treated with DUPIXENT.
Individual results may vary.
|
|
|
|
|
|
|
|
In a clinical trial of patients 6 months to 5 years of age with uncontrolled moderate-to-severe atopic dermatitis, DUPIXENT has proven efficacy and a demonstrated safety profile.1
|
|
|
|
PROVEN ITCH REDUCTION2
48% of infants to preschoolers treated with DUPIXENT + TCS (n=83) achieved ≥4-point reduction in Worst Scratch/Itch NRS at Week 16 in AD-1539 vs 9% with placebo + TCS (n=79); P<0.0001, secondary endpoint
|
|
|
|
|
IMPROVEMENT IN SKIN LESIONS2
53% of infants to preschoolers treated with DUPIXENT + TCS (n=83) achieved ≥75% improvement in lesion extent and severity (EASI-75) at Week 16 vs 11% with placebo + TCS (n=79); P<0.0001, secondary endpoint
|
|
|
|
|
SIMILAR DEMONSTRATED SAFETY PROFILE
IN INFANTS AND ADULTS1
The safety profile of DUPIXENT + TCS in infants to preschoolers through Week 16 was similar to that in adults with atopic dermatitis
|
|
|
The most common adverse reactions (incidence ≥1%) are injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, dry eye, and eosinophilia.1
PRIMARY ENDPOINT: Proportion of subjects with an IGA 0 (clear) or 1 (almost clear) at Week 16 (28% of patients treated with DUPIXENT + TCS vs 4% with placebo + TCS, P<0.0001).1,2
TRIAL DESIGN: 162 infants to preschoolers (6 months to 5 years) in AD-1539 (16 weeks) with moderate-to-severe atopic dermatitis inadequately controlled with topical prescription therapies were randomized to DUPIXENT + TCS or placebo + TCS. Patients ≥15 kg but <30 kg received 300 mg Q4W. Patients ≥5 kg but <15 kg received 200 mg Q4W. Patients had an IGA score ≥3 on a scale of 0 to 4, an EASI score ≥16 on a scale of 0 to 72, and BSA involvement of ≥10%. At baseline, 23% of infants to preschoolers had an IGA score of 3 (moderate), 77% had an IGA of 4 (severe), mean EASI score was 34.1, and weekly average of daily Worst Scratch/Itch NRS was 7.6 on a scale of 0 to 10.1,2
|
|
|
|
IMPORTANT SAFETY INFORMATION (cont’d)
|
|
WARNINGS AND PRECAUTIONS
Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, serum sickness or serum sickness-like reactions, angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme have been reported. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.
Conjunctivitis and Keratitis: Conjunctivitis and keratitis occurred more frequently in atopic dermatitis subjects who received DUPIXENT versus placebo. Conjunctivitis was the most frequently reported eye disorder. Most subjects with conjunctivitis or keratitis recovered or were recovering during the treatment period. Conjunctivitis and keratitis have been reported with DUPIXENT in postmarketing settings, predominantly in atopic dermatitis patients. Some patients reported visual disturbances (e.g., blurred vision) associated with conjunctivitis or keratitis. Advise patients to report new onset or worsening eye symptoms to their healthcare provider. Consider ophthalmological examination for patients who develop conjunctivitis that does not resolve following standard treatment or signs and symptoms suggestive of keratitis, as appropriate.
Risk Associated with Abrupt Reduction of Corticosteroid Dosage: Do not discontinue systemic, topical, or inhaled corticosteroids abruptly upon initiation of DUPIXENT. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a healthcare provider. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.
Atopic Dermatitis Patients with Co-morbid Asthma: Advise patients not to adjust or stop their asthma treatments without consultation with their physicians.
Arthralgia: Arthralgia has been reported with the use of DUPIXENT with some patients reporting gait disturbances or decreased mobility associated with joint symptoms; some cases resulted in hospitalization. Advise patients to report new onset or worsening joint symptoms. If symptoms persist or worsen, consider rheumatological evaluation and/or discontinuation of DUPIXENT.
Parasitic (Helminth) Infections: It is unknown if DUPIXENT will influence the immune response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with DUPIXENT. If patients become infected while receiving treatment with DUPIXENT and do not respond to anti-helminth treatment, discontinue treatment with DUPIXENT until the infection resolves.
Vaccinations: Consider completing all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating DUPIXENT. Avoid use of live vaccines during treatment with DUPIXENT.
ADVERSE REACTIONS: The most common adverse reactions (incidence ≥1%) in patients with atopic dermatitis are injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, dry eye, and eosinophilia. The safety profile in pediatric patients through Week 16 was similar to that of adults with atopic dermatitis. In an open-label extension study, the long-term safety profile of DUPIXENT ± TCS in pediatric patients observed through Week 52 was consistent with that seen in adults with atopic dermatitis, with hand-foot-and-mouth disease and skin papilloma (incidence ≥2%) reported in patients 6 months to 5 years of age. These cases did not lead to study drug discontinuation.
|
|
USE IN SPECIFIC POPULATIONS
|
|
•
|
Pregnancy: A pregnancy exposure registry monitors pregnancy outcomes in women exposed to DUPIXENT during pregnancy. To enroll or obtain information call 1-877-311-8972 or go to https://mothertobaby.org/ongoing-study/dupixent/. Available data from case reports and case series with DUPIXENT use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Human IgG antibodies are known to cross the placental barrier; therefore, DUPIXENT may be transmitted from the mother to the developing fetus.
|
|
•
|
Lactation: There are no data on the presence of DUPIXENT in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for DUPIXENT and any potential adverse effects on the breastfed child from DUPIXENT or from the underlying maternal condition.
|
|
|
Click here for full Prescribing Information.
|
|
BSA, body surface area; EASI, Eczema Area and Severity Index; IGA, Investigator’s Global Assessment; NRS, numerical rating scale; Q4W, once every 4 weeks; TCS, topical corticosteroids.
References: 1. DUPIXENT Prescribing Information. 2. Paller AS, Simpson EL, Siegfried EC, et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2022;400(10356):908-919.
|
|
|
US.DUP.24.03.0059
|
|
|
© 2024 Sanofi and Regeneron Pharmaceuticals, Inc.
All Rights Reserved.
DUPIXENT® is a registered trademark of Sanofi Biotechnology.
Regeneron Corporate Headquarters
777 Old Saw Mill River Road
Tarrytown, NY 10591
Privacy Policy
Sanofi US
55 Corporate Drive
Bridgewater, NJ 08807
Privacy Policy
|
|
|
|
|
|
